Edition:
India

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

3.59USD
19 Jan 2018
Change (% chg)

$-0.01 (-0.28%)
Prev Close
$3.60
Open
$3.54
Day's High
$3.88
Day's Low
$3.54
Volume
61,765
Avg. Vol
102,963
52-wk High
$22.16
52-wk Low
$3.21

Summary

Name Age Since Current Position

Ray Prudo

2017 Chairman of the Board

David Solomon

57 2017 Chief Executive Officer

Dov Elefant

47 2012 Chief Financial Officer

Clive Richardson

2015 Chief Operating Officer, Director

Nigel Hernandez

2017 Vice President - Worldwide Regulatory Affairs

David Byrne

2016 Director

Robert Ward

59 2016 Director

Donald Williams

57 2016 Director

James Hill

2015 Non-Executive Director

Stuart Ungar

2015 Non-Executive Director

Biographies

Name Description

Ray Prudo

David Solomon

Dr. David Horn Solomon has been appointed as Chief Executive Officer of the Comapny, with effective from August 28, 2017. Dr David Horn Solomon was the CEO of Zealand Pharma A/S (NASDAQ:ZEAL) from 2008 to 2015. Under David's leadership the company went public on NASDAQ OMX in Copenhagen and its lead product, Adlixin®, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved in the US and globally and is now marketed by Sanofi as a monotherapy and in combination with Lantus as Soliqua®. David was also the CEO of Bionor Pharma ASA (OSL:BIONOR) and until his appointment at Akari was the Managing Partner of Sund Capital, a Nordic healthcare investment fund. Dr Solomon studied at Weil Cornell Medicine of Cornell University and its Graduate School of Medical Science where he received his Ph.D.

Dov Elefant

Mr. Dov Elefant has served as our Chief Financial Officer of Celsus Therapeutics PLC since January 11, 2012. From March 2011 until January 2012, he was Chief Financial Officer of Althera Medical Ltd. and from March 2009 to February 2011 he performed consulting services to a number of companies. He was also the Corporate Controller, from March 2007 to February 2009 for Lev Pharmaceuticals (OTCBB:LEVP), which was acquired by ViroPharma in 2008, Controller and Vice President of Finance and Administration at EpiCept Corporation (NASDAQ:EPCT.PK) from December 1999 to March 2007, Assistant Controller at Tetragenex Pharmaceuticals from November 1998 to October 1999 and held other accounting and finance roles from March 1991 to October 1998. Mr. Elefant holds a B.S. in accounting from Yeshiva University.

Clive Richardson

Nigel Hernandez

Mr. Nigel A.S. Hernandez, Ph.D., serves as Vice President - Worldwide Regulatory Affairs of the Company. Nigel Hernandez, PhD, MSc, RAC joined Akari as Vice President of Worldwide Regulatory Affairs. Nigel has more than 20 years of global regulatory experience (nonclinical through commercial) in the pharmaceutical industry. He began his regulatory career at Biopure, then worked at LeukoSite (acquired by Millennium), Millennium Pharmaceuticals, GMP Regulatory, Archemix Corp, ARIAD Pharmaceuticals and Tarsa Therapeutics, where he held roles of increasing responsibility. At Actelion Pharmaceuticals, he was responsible for global regulatory leadership and strategy for Veletri (epoprostenol) and Zavesca (miglustat), including several early and late-stage developmental products in the cardiovascular, oncology and neurology therapeutic areas. He was most recently at Esperion Therapeutics where he led the global regulatory development of bempedoic acid to lower elevated levels of low-density lipoprotein cholesterol (LDL-C).

David Byrne

Robert Ward

Mr. Robert E. Ward is a Director of the Company. Mr. Ward serves as President and Chief Executive Officer and a member of the Board of Radius Health, Inc., a NASDAQ listed biopharmaceutical company, since December 2013. During his tenure, Radius Health has completed late stage development of its lead compound and filed the first global regulatory new drug applications, successfully raised over $750 million in private and public financings – including an initial public offering in 2014, and advanced other novel compounds/drug delivery technologies in clinical development. Prior to leading Radius, Mr. Ward was Vice President for Strategy and External Alliances for AstraZeneca (AZ).

Donald Williams

Mr. Donald A. Williams is a Director of the Company. Mr. Williams is a 35-year veteran of the public accounting industry. Mr. Williams spent 18 years as a partner at Ernst & Young and the last seven years as a partner at Grant Thornton. Mr. Williams' career focused on private and public companies in the technology and life sciences sectors. During the last seven years at Grant Thornton, he served as the National Leader of Grant Thornton's Life Sciences Practice and the Managing Partner of the San Diego Office.

James Hill

Stuart Ungar

Basic Compensation